Hepaxa Management of Non-alcoholic Fatty Liver Disease

Subjects With fatty liver are given Hepaxa for 6 months. Fibroscan CAP measurements are taken
at 3 monthly intervals. Subjects consent to Collection of data from approximately 6 months
prior to use of Hepaxa. Patients unresponsive to life style recommendations given as standard
practice will be enrolled.

Inclusion Criteria:

1. Men or women, ≥18 years of age.

2. Suspicion of NAFLD

3. Able to understand and cooperate with study procedures, and have signed a written
informed consent prior to any study procedures.

4. CAP score at -6 months and at inclusion of >268

5. A fibroscan elastography score <9 Kpa (Advanced Fibrosis)

Exclusion Criteria:

1. Other causes of liver inflammation including Hepatitis A, B or C, HIV, confirmed or
suspected cirrhosis, Wilson's disease, autoimmune hepatitis, hemochromatosis,
alcoholic steatohepatitis, pancreatitis, or prescription medications known to cause
liver damage, or known to be hepatotoxic.

2. Significant weight loss (> 5% body weight) or rapid weight loss (>1.6 kg/week), within
six months of screening.

3. Individuals taking prescription or supplemental omega-3 fatty acids.

4. Has a condition the Investigator believes would interfere with the evaluation of the
subject, or may put the subject at undue risk during the course of the study,
including potentially abnormal lab results, due to a traumatic event.